All Updates

All Updates

icon
Filter
Partnerships
AQEMIA and Sanofi collaborate to discover small-molecule drug candidates
AI Drug Discovery
Dec 5, 2023
This week:
Product updates
Rockwell Automation to launch AI and robotics solutions at ADIPEC 2024
Smart Factory
Oct 30, 2024
Product updates
OpenAI adds new voices and reduces prices for Realtime API
Foundation Models
Oct 30, 2024
Funding
Eve Air Mobility raises USD 50 million in bank loan from Citibank
Passenger eVTOL Aircraft
Oct 30, 2024
Partnerships
Aitia expands partnership with Servier to discover treatments for gliomas
AI Drug Discovery
Oct 30, 2024
M&A
Kapoose Creek Bio acquires Adapsyn Bioscience's drug discovery lab and informatics platform for undisclosed sum
AI Drug Discovery
Oct 30, 2024
Funding
Axonis Therapeutics raises USD 115 million in Series A funding to develop AXN-027 neurology treatment
Precision Medicine
Oct 30, 2024
Partnerships
Cornerstone and Meta enter strategic partnership to revolutionize immersive learning and AI-powered workforce development
Extended Reality
Oct 30, 2024
Product updates
Funding
NextSilicon launches Maverick-2 intelligent compute accelerator and raises funding for high-performance compute
Generative AI Infrastructure
Oct 30, 2024
Product updates
Funding
Verax AI raises USD 7.6 million in seed funding for improved visibility and control of AI in production
Generative AI Infrastructure
Oct 30, 2024
M&A
Financial Finesse acquires OfColor for undisclosed amount
Financial Wellness Tools
Oct 30, 2024
AI Drug Discovery

AI Drug Discovery

Dec 5, 2023

AQEMIA and Sanofi collaborate to discover small-molecule drug candidates

Partnerships

  • AI drug discovery company AQEMIA and Sanofi have entered a multi-year research collaboration to accelerate the research and development of small molecule drug candidates.

  • As part of the agreement, AQEMIA will receive an upfront payment and up to USD 140 million in milestone payments. Sanofi will be responsible for laboratory research, development, and commercial activities of the drug candidates.

  • The partnership will leverage AQEMIA's deep physics platform combined with GenAI and Sanofi’s global R&D expertise to accelerate the design of novel drug molecules for Sanofi’s selected therapeutic targets. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.